CVS Health (NYSE:CVS) Given New $107.00 Price Target at Barclays

Posted by Brian Himes on Nov 5th, 2026

CVS Health (NYSE:CVS – Get Free Report) had its target price cut by stock analysts at Barclays from $108.00 to $107.00 in a report issued on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the pharmacy operator’s stock. Barclays‘s price target would suggest a potential upside of 33.53% from the company’s previous close.

A number of other analysts have also commented on the company. TD Cowen restated a “buy” rating on shares of CVS Health in a report on Wednesday. Piper Sandler set a $112.00 price objective on shares of CVS Health in a report on Wednesday, September 9th. Wells Fargo & Company lifted their target price on CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. UBS Group set a $110.00 price target on shares of CVS Health in a research report on Wednesday. Finally, Wall Street Zen downgraded shares of CVS Health from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 19th. Twenty-two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $109.42.

Check Out Our Latest Research Report on CVS Health

CVS Health Stock Up 0.2%

NYSE CVS traded up $0.17 during trading hours on Thursday, reaching $80.13. 10,231,981 shares of the company’s stock were exchanged, compared to its average volume of 8,469,738. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The company has a market capitalization of $102.49 billion, a price-to-earnings ratio of 21.18, a price-to-earnings-growth ratio of 0.85 and a beta of 0.58. The company’s 50-day moving average is $90.82 and its two-hundred day moving average is $88.86. CVS Health has a one year low of $69.51 and a one year high of $110.68.

CVS Health (NYSE:CVS – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The pharmacy operator reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.65 by $0.44. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company had revenue of $108.40 billion during the quarter, compared to analysts’ expectations of $104.72 billion. During the same quarter in the prior year, the company earned $1.60 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. On average, analysts forecast that CVS Health will post 8.02 EPS for the current fiscal year.

Institutional Trading of CVS Health

Several hedge funds have recently added to or reduced their stakes in the company. Kilter Group LLC acquired a new stake in CVS Health during the second quarter worth approximately $27,000. Beaird Harris Wealth Management LLC increased its holdings in CVS Health by 201.0% in the 2nd quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator’s stock valued at $30,000 after buying an additional 195 shares during the period. J.Safra Asset Management Corp acquired a new position in shares of CVS Health in the 2nd quarter valued at approximately $30,000. Timbuktu Capital Management LLC bought a new stake in shares of CVS Health during the 2nd quarter worth approximately $31,000. Finally, Dunhill Financial LLC bought a new position in CVS Health in the second quarter valued at approximately $32,000. 80.66% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

Positive Sentiment: CVS reported third-quarter adjusted earnings of $2.09 per share, above the roughly $1.65 consensus, while revenue rose 5.4% year over year to $108.4 billion. Management also raised its 2026 adjusted EPS outlook to at least $8.20 and operating cash flow guidance to at least $15.5 billion. Read More.
Neutral Sentiment: The company plans to separate its retail pharmacy business from Aetna, Caremark and related healthcare operations, aiming to create two publicly traded companies by the first half of 2028. The separation could let each business focus on its own operations, but the potential value for shareholders will depend on how it is structured and executed. Read More.
Negative Sentiment: The breakup announcement has overshadowed the earnings beat. Investors may be concerned about the execution risks of separating the businesses, including how debt and costs will be allocated and whether the companies can maintain the benefits of their existing integration. Read More.

About CVS Health

(Get Free Report)

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.